Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Ann Neurol. 2019 Jul 30;86(3):384–394. doi: 10.1002/ana.25545

Figure 3.

Figure 3.

Plasma sST2 and outcome in the Copenhagen cohort. A) sST2 over time was also significantly higher in those with poor outcome in the Copenhagen cohort (analysis of response profiles, p = 0.002). B) Similar results were seen for mortality, with sST2 again higher over time in those who died, but this different did not meet the threshold for significance (p < 0.0001). C) In an effort to replicate the Boston cohort results, sST2 concentration at day 3 after ictus, corresponding to the median day of the early timepoint in the Boston cohort, was compared between those with good and poor outcome. Median day 3 sST2 concentration was higher in those with poor outcome (188.5 [IQR 87.4 – 317.6] ng/mL versus 94.3 [IQR 47.2 – 114.5] ng/mL, p = 0.012).